Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

AstraZeneca

Status and phase: Withdrawn; Phase 1

Conditions: Epithelial Ovarian Cancer; Non Small Cell Lung Cancer; Cancer

Treatments: Drug: AZD0530; Drug: Carboplatin; Drug: paclitaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT01000896

D8180C00020

Details and patient eligibility

About

The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.

Enrollment: 27 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese patients with non small cell lung cancer or epithelial ovarian cancer
• Must be suitable for treatment with carboplatin and paclitaxel
• Relatively good overall health other than cancer

Exclusion criteria

• Poor bone marrow function (not producing enough blood cells).
• Poor liver or kidney function.
• Patients unable to discontinue drugs known to be potent inhibitors or inducers of CYP3A4 within 2 weeks prior to registration

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

27 participants in 1 patient group

AZD0530 + carboplatin and paclitaxel

Experimental group

Description:

AZD0530 in combination with carboplatin and paclitaxel

Treatment:

Drug: paclitaxel

Drug: Carboplatin

Drug: AZD0530